Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447211 | 1.00 | NPSR1 (0.38) | NPSR1HCAR2ALDH1A1MAPTMETAP1 | |
| SCHEMBL4447215 | 1.00 | NPSR1 (0.38) | NPSR1HCAR2ALDH1A1MAPTMETAP1 | |
| SCHEMBL6067588 | 0.82 | NPSR1 (0.38) | NPSR1HCAR2ALDH1A1MAPT | |
| SCHEMBL6067591 | 0.82 | NPSR1 (0.38) | NPSR1HCAR2ALDH1A1MAPT | |
| SCHEMBL4448957 | 0.82 | NPSR1 (0.38) | NPSR1HCAR2ALDH1A1MAPT | |
| SCHEMBL4448959 | 0.82 | NPSR1 (0.38) | NPSR1HCAR2ALDH1A1MAPT | |
| SCHEMBL4448960 | 0.82 | NPSR1 (0.38) | NPSR1HCAR2ALDH1A1MAPT | |
| SCHEMBL6504169 | 0.78 | NPSR1 (0.42) | NPSR1HCAR2ALDH1A1MAPTMETAP1 | |
| SCHEMBL4446758 | 0.78 | NPSR1 (0.42) | NPSR1HCAR2ALDH1A1MAPTMETAP1 | |
| SCHEMBL6504174 | 0.78 | NPSR1 (0.42) | NPSR1HCAR2ALDH1A1MAPTMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070191350-A1 | Combinations comprising alpha-2-delta ligands | PIFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1727535-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | Pfizer Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005102390-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND NMDA RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005092318-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | NPSR1 580/4885HCAR2 766/4885ALDH1A1 1484/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | NPSR1 605/4885HCAR2 617/4885ALDH1A1 1627/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | NPSR1 561/4885HCAR2 647/4885ALDH1A1 1424/4885 |
| US-20070191350-A1 | Combinations comprising alpha-2-delta ligands | OPRD1, CHRND, OPRL1 | NPSR1 59/4885HCAR2 497/4885ALDH1A1 2062/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | NPSR1 113/4885HCAR2 214/4885ALDH1A1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.